Qsymia set for US launch and Belviq waits out classification as Contrave CV trial speeds ahead
This article was originally published in Scrip
Orexigen Therapeutics reported on 5 September that it has achieved faster than anticipated patient enrolment in the cardiovascular outcomes trial (CVOT) requested by the US FDA earlier this year for the San Diego-based company's Contrave (naltrexone SR/bupropion SR), which could indicate strong patient demand for weight loss drugs generally, according to at least one equity analyst that follows competitors in the obesity market.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.